<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6096">
  <stage>Registered</stage>
  <submitdate>16/09/2016</submitdate>
  <approvaldate>16/09/2016</approvaldate>
  <nctid>NCT02911792</nctid>
  <trial_identification>
    <studytitle>Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration</studytitle>
    <scientifictitle>Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration</scientifictitle>
    <utrn />
    <trialacronym>Hyper</trialacronym>
    <secondaryid>HSC20160262H</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dapagliflozin
Treatment: drugs - Metformin

Experimental: Dapagliflozin - Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day

Active Comparator: Metformin - Subjects will be randomized to metformin-XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).


Treatment: drugs: Dapagliflozin
SGLT2 inhibitor

Treatment: drugs: Metformin
Oral diabetes medicine that helps control blood sugar levels.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>GFR (glomerular filtration rate) change after treatment with Dapagliflozin - Change from baseline in GFR after treatment with dapagliflozin for 4 months in the hyperfiltering diabetic group</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>GFR (glomerular filtration rate) change after treatment with Metformin - Change from baseline in GFR after treatment with metformin for 4 months in the hyperfiltering diabetic group</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>GFR (glomerular filtration rate) change after treatment with Dapagliflozin in normofiltering group - Change from baseline in GFR in the normofiltering group following 4 months of treatment with dapagliflozin</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Newly diagnosed, drug naïve, hyperfiltering and normofiltration patients with type 2
             diabetes mellitus (T2DM)

          -  Hyperfiltration is defined by GFR &gt;135 ml/min1.73m2

          -  Normofiltration by a GFR = 90-134 ml/min1.73m2

          -  BMI = 20-45 kg/m2

          -  HbA1c = 7.5% to 12%

          -  Willingness to participate in the 16 week study protocol

          -  Hematocrit &gt;34%

          -  GAD antibody negative

          -  BP &lt; 145/90 mmHg</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  &gt; 300 mg/day albumin excretion

          -  Ingestion of medications known to interfere with the renin-angiotensin system or renal
             function, including diuretic therapy

          -  Hospitalization for unstable angina, history of recent macrovascular
             (MI/stroke/TIA/ACS) disease, coronary artery revascularization (within 2 months prior
             to enrollment)

          -  Proliferative diabetic retinopathy

          -  History of cancer or major organ system disease

          -  New York Heart class II-IV heart failure Severe hepatic insufficiency and/or
             significant abnormal liver function defined as aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) &gt; 3x ULN or total bilirubin &gt; 2.0 mg/dL (34.2 µmo/L)

          -  Treatment with steroids, beta blockers, alpha blockers, antiobesity drugs

          -  Pregnant or nursing mothers

          -  Premenopausal females who are not practicing acceptable contraceptive methods
             Participation in another trial with an investigational drug within 30 days Alcohol or
             drug abuse within the preceding 6 months

          -  Any condition, psychiatric or medical, which in the opinion of the investigator would
             interfere with the successful completion of the study

          -  Orthostatic hypotension (&gt; 15/10 mmHg decrease upon standing for 3 minutes)

          -  Positive serologic evidence of current infectious liver disease including Hepatitis B
             viral antibody IGM, Hepatitis B surface antigen, Hepatitis C virus antibody and HIV

          -  Volume depleted patients

          -  Estimated glomerular filtration rate &lt;60 mL/min1.73m2. Patients at risk for volume
             depletion due to co-existing conditions or concomitant medications, such as loop
             diuretics should have careful monitoring of their volume status</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Baker Medical Research Institute and Alfred Hospital - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Texas Health Science Center at San Antonio</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>AstraZeneca</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or
      without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated
      group will serve as controls for improved glycemic control, since the investigators have
      shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM
      patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02911792</trialwebsite>
    <publication>Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010 Oct;53(10):2093-104. doi: 10.1007/s00125-010-1794-9. Epub 2010 May 23. Review.
Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009 Apr;52(4):691-7. doi: 10.1007/s00125-009-1268-0. Epub 2009 Feb 7.
Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med. 1991 Jun 6;324(23):1626-32. Erratum in: N Engl J Med 1991 Dec 5;325(23):1666.
Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014 Feb 4;129(5):542-4. doi: 10.1161/CIRCULATIONAHA.113.007071. Epub 2013 Dec 13.
Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011 Aug;32(4):515-31. doi: 10.1210/er.2010-0029. Epub 2011 May 23. Review.
Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999 Dec;10(12):2569-76.
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.
Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986 Jun;77(6):1925-30.
Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000 May;57(5):1803-17. Review.
Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications. 1995 Oct-Dec;9(4):304-7. Review.
Ellis EN, Steffes MW, Goetz FC, Sutherland DE, Mauer SM. Glomerular filtration surface in type I diabetes mellitus. Kidney Int. 1986 Apr;29(4):889-94.
Schwieger J, Fine LG. Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus. N Engl J Med 312:617-21, 1985
Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res. 2008;2008:305403. doi: 10.1155/2008/305403.
Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R75-83. doi: 10.1152/ajpregu.00357.2011. Epub 2011 Sep 21.
Pei F, Li BY, Zhang Z, Yu F, Li XL, Lu WD, Cai Q, Gao HQ, Shen L. Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice. J Diabetes Complications. 2014 Sep-Oct;28(5):596-603. doi: 10.1016/j.jdiacomp.2014.04.010. Epub 2014 Apr 24.
Bakker J, Olree M, Kaatee R, de Lange EE, Moons KG, Beutler JJ, Beek FJ. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology. 1999 Jun;211(3):623-8.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>